Sunshine Biopharma (SBFM) Accumulated Depreciation & Amortization (2022 - 2025)
Sunshine Biopharma (SBFM) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $412626.0 as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $412626.0, compared with a TTM value of $412626.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $336533.0, up 77.13% over the prior year.
- Accumulated Depreciation & Amortization was $412626.0 for Q2 2025 at Sunshine Biopharma, up from $336533.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $412626.0 in Q2 2025 and bottomed at $83806.0 in Q4 2022.
- Average Accumulated Depreciation & Amortization over 4 years is $255740.2, with a median of $263264.5 recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization soared 126.71% in 2023, then surged 77.13% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $83806.0 in 2022, then skyrocketed by 126.71% to $189996.0 in 2023, then soared by 77.13% to $336533.0 in 2024, then increased by 22.61% to $412626.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for SBFM at $412626.0 in Q2 2025, $336533.0 in Q4 2024, and $189996.0 in Q4 2023.